docetaxel [Ligand Id: 6809] activity data from GtoPdb and ChEMBL

Click here for a description of the charts and data table

Please tell us if you are using this feature and what you think!

ChEMBL ligand: CHEMBL92 (Bind 014, Cabazitaxel metabolite (rp56976), CKD-810, Docefrez, Docetaxel anhydrous, Docetaxel, anhydrous, Docetaxel kabi, Docetaxel mylan, Docetaxel teva pharma, Docetaxel winthrop, NSC-628503, Rp56976)
  • nucleotide binding oligomerization domain containing 2/Nucleotide-binding oligomerization domain-containing protein 2 in Human [ChEMBL: CHEMBL1293266] [GtoPdb: 1763] [UniProtKB: Q9HC29]
There should be some charts here, you may need to enable JavaScript!
There should be some charts here, you may need to enable JavaScript!
DB Assay description Assay Type Standard value Standard parameter Original value Original units Original parameter Reference
nucleotide binding oligomerization domain containing 2/Nucleotide-binding oligomerization domain-containing protein 2 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1293266] [GtoPdb: 1763] [UniProtKB: Q9HC29]
ChEMBL Inhibition of MDP-induced human NOD2 signaling expressed in HEK-Blue cells preincubated for 3 hrs followed by MDP-stimulation for 20 hrs by spectrophotometry based SEAP reporter gene assay B 5.3 pIC50 5011.87 nM IC50 J Med Chem (2017) 60: 1219-1224 [PMID:28075581]
tubulin beta class I/tubulin alpha 4a/tubulin beta 4B class IVb/tubulin beta 3 class III/tubulin beta 8 class VIII/tubulin alpha 1a/Tubulin in Human (target type: PROTEIN COMPLEX GROUP) [ChEMBL: CHEMBL2095182] [GtoPdb: 2640, 2639, 2641, 2752, 2753, 2638] [UniProtKB: P04350, P07437, P0DPH7, P68363, P68366, P68371, Q13509, Q13885, Q3ZCM7, Q6PEY2, Q71U36, Q9BQE3, Q9BUF5, Q9BVA1, Q9H4B7]
ChEMBL Inhibition of microtubule (unknown origin) polymerization B 6.7 pIC50 200 nM IC50 Eur J Med Chem (2023) 262: 115925-115925 [PMID:37948954]
ChEMBL Inhibition of microtubule polymerization in human HCT-116 cells B 6.7 pIC50 200 nM IC50 Eur J Med Chem (2023) 262: 115928-115928 [PMID:37944387]

ChEMBL data shown on this page come from version 36:

Zdrazil B, Felix E, Hunter F, Manners EJ, Blackshaw J, Corbett S, de Veij M, Ioannidis H, Lopez DM, Mosquera JF, Magarinos MP, Bosc N, Arcila R, Kizilören T, Gaulton A, Bento AP, Adasme MF, Monecke P, Landrum GA, Leach AR. (2024). The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods. Nucleic Acids Res., 52(D1). DOI: 10.1093/nar/gkad1004. [EPMCID:10767899] [PMID:37933841]
Davies M, Nowotka M, Papadatos G, Dedman N, Gaulton A, Atkinson F, Bellis L, Overington JP. (2015) 'ChEMBL web services: streamlining access to drug discovery data and utilities.' Nucleic Acids Res., 43(W1). DOI: 10.1093/nar/gkv352. [EPMCID:25883136]